Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology.

PURPOSE To develop a public-private partnership to study the feasibility of a new approach in collecting and analyzing clinically annotated imaging data from landmark phase III trials in advanced solid tumors. PATIENTS AND METHODS The collection of clinical trials fulfilled the following inclusion criteria: completed randomized trials of > 300 patients, highly measurable solid tumors (non-small-cell lung cancer, colorectal cancer, renal cell cancer, and melanoma), and required sponsor and institutional review board sign-offs. The new approach in analyzing computed tomography scans was to transfer to an academic image analysis laboratory, draw contours semi-automatically by using in-house-developed algorithms integrated into the open source imaging platform Weasis, and perform serial volumetric measurement. RESULTS The median duration of contracting with five sponsors was 12 months. Ten trials in 7,085 patients that covered 12 treatment regimens across 20 trial arms were collected. To date, four trials in 3,954 patients were analyzed. Source imaging data were transferred to the academic core from 97% of trial patients (n = 3,837). Tumor imaging measurements were extracted from 82% of transferred computed tomography scans (n = 3,162). Causes of extraction failure were nonmeasurable disease (n = 392), single imaging time point (n = 224), and secondary captured images (n = 59). Overall, clinically annotated imaging data were extracted in 79% of patients (n = 3,055), and the primary trial end point analysis in each trial remained representative of each original trial end point. CONCLUSION The sharing and analysis of source imaging data from large randomized trials is feasible and offer a rich and reusable, but largely untapped, resource for future research on novel trial-level response and progression imaging metrics.

[1]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[2]  Lawrence H. Schwartz,et al.  A Response Assessment Platform for Development and Validation of Imaging Biomarkers in Oncology , 2016, Tomography.

[3]  L. Schwartz,et al.  Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors. , 2016, JAMA oncology.

[4]  W. Tsai,et al.  Reproducibility of radiomics for deciphering tumor phenotype with imaging , 2016, Scientific Reports.

[5]  M. Maitland,et al.  Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling , 2016, Clinical and translational science.

[6]  L. Schwartz,et al.  Semiautomatic segmentation of liver metastases on volumetric CT images. , 2015, Medical physics.

[7]  M. Burotto,et al.  Pseudoprogression and Immune-Related Response in Solid Tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Wei Zhou,et al.  Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.

[9]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[10]  J. Tabernero,et al.  Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. , 2014 .

[11]  L. Schwartz,et al.  Response phenotype as a predictive biomarker to guide treatment with targeted therapies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Binsheng Zhao,et al.  Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals. , 2013, European journal of radiology.

[13]  Yi-long Wu,et al.  LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. , 2013 .

[14]  L. Schwartz,et al.  Segmentation of lung lesions on CT scans using watershed, active contours, and Markov random field. , 2013, Medical physics.

[15]  E. Van Cutsem,et al.  Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Schwartz,et al.  When progressive disease does not mean treatment failure: reconsidering the criteria for progression. , 2012, Journal of the National Cancer Institute.

[17]  J Jack Lee,et al.  Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Sequist,et al.  LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Yan Sun,et al.  Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. , 2012, The Lancet. Oncology.

[20]  G. Pond,et al.  Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. , 2012, Journal of the National Cancer Institute.

[21]  S. Bates,et al.  Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth , 2012, Clinical Cancer Research.

[22]  M. Maitland,et al.  Clinical trials in the era of personalized oncology , 2011, CA: a cancer journal for clinicians.

[23]  M. Maitland,et al.  A time to keep and a time to cast away categories of tumor response. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Josep Tabernero,et al.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Michael L Maitland,et al.  Volumes to Learn: Advancing Therapeutics with Innovative Computed Tomography Image Data Analysis , 2010, Clinical Cancer Research.

[26]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Binsheng Zhao,et al.  Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. , 2009, Radiology.

[28]  Haesun Choi,et al.  We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Joseph A DiMasi,et al.  Economics of new oncology drug development. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Van V. Brantner,et al.  Estimating the cost of new drug development: is it really 802 million dollars? , 2006, Health affairs.

[31]  Wendy Brown,et al.  Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  E. Van Cutsem,et al.  Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. , 2014, European journal of cancer.

[33]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[34]  L. Tanoue,et al.  Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes , 2012 .